article
Home » Archives for article
Scientists release paper on subsea plumes in Gulf
Thursday, August 19th, 2010
NEW YORK (MarketWatch) — Scientists at the Woods Hole Oceanographic Institution measured a plume of hydrocarbons at least 22 miles long and more than 3,000 feet below the surface of the Gulf of Mexico as residue of the BP PLC Deepwater Horizon oil spill, according to an article released on Thursday. “Deep-sea microbes were degrading the plume relatively slowly, and that it was possible that the plume had and will persist for some time,” the article said. The team combed through 57,000 discrete chemical analyses measured in real time during a June 19-28 scientific cruise aboard the R/V Endeavor.
Posted in: headlines | 0 Comments »
Read the full story
ISCT works with industry to launch cell therapy partnership
Monday, August 16th, 2010
Biotech firms Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies are
Posted in: Pharma News | 0 Comments »
Read the full story
The FDA and drug companies: Too cozy a relationship ?
Saturday, August 14th, 2010
There is an interesting article in this weeks Time Magazine on Avandia and the FDA. At best it paints a picture of an agency too cozy with drug companies, at its worst it suggests that GSK knew the risks of Avandia and was more interested in sales than patient safety. Here are some excepts from the article: The most recent studies of Avandia, the GSK officials told the FDA, had “yielded information that is inconsistent with an increased risk of myocardial ischemic events,” according to sealed court proceedings obtained by TIME
Posted in: DTC | 0 Comments »
Read the full story
Cardiome shares sag after Merck delays PhIII study
Thursday, August 12th, 2010
Investors in Canada’s Cardiome Pharma ( CRME ) are more than a little disappointed to hear that
Posted in: Pharma News | 0 Comments »
Read the full story
Cardioxyl gets $15M and positive data on lead program
Monday, August 2nd, 2010
Cardioxyl Pharmaceuticals has rounded up $15 million and positive early-stage safety data, positioning the start-up developer for a mid-stage clinical trial of its lead therapy for cardiovascular disease. Aurora Funds and New Enterprise Associates provided the fresh infusion of cash. Researchers investigated CXL-1020 in 28 patients at seven sites, citing positive safety and tolerability results for the subjects suffering from chronic stable heart failure
Posted in: Pharma News | 0 Comments »
Read the full story
Cytori gains European OK for stem cell tech
Tuesday, July 27th, 2010
Shares of Cytori Therapeutics ( CYTX ) were buoyed by the news that European regulators have approved its stem cell technology for a range of procedures including breast reconstruction surgery and tissue repair.
Posted in: Pharma News | 0 Comments »
Read the full story
DMC: Novartis’ drug safe but not effective in mid-study analysis
Friday, July 23rd, 2010
An independent data monitoring committee (DMC) has
Posted in: Pharma News | 0 Comments »
Read the full story
Cancer Vaccines: Northwest Biotherapeutics vs. Dendreon
Friday, July 16th, 2010
M.E. Garza submits: As a followup to our interview with Northwest Biotherapeutics’ ( NWBO.OB ) Chairman of the Board of Linda Powers, this article focuses on the “hard differentiators” between NWBO’s immunotherapy vaccine platform and that of their closest competitor Dendreon Corporation ( DNDN )
Posted in: Pharma News | 0 Comments »
Read the full story
An Avandia Study Author…Or So We Thought?
Tuesday, July 13th, 2010
Steve Haffner played a relatively modest role in the Avandia scandal, but until now, he was known primarily for leaking to GlaxoSmithkline the damaging meta-analysis of the diabetes pill that was published in The New England Journal of Medicine three years ago. Haffner later acknowledged breaching his responsibility as a peer reviewer, but blamed “bad judgment” because he wasn’t “feeling well.” In doing so, Glaxo was able to respond very quickly to the disclosure ( back story ). As it happens, Haffner felt just fine several years earlier when he allegedly had an Avandia study ghostwritten for him
Posted in: Pharma News | 0 Comments »
Read the full story
Hmmm: The Gates Foundation Bails
Tuesday, July 13th, 2010
According to this piece , the Gates Foundation unloaded basically all of its pharma and biotech stock holdings during the second quarter. Merck/Schering-Plough, J&J, Lilly, through Vertex and all the way to InterMune, Allos, and Auxilium – they held millions of shares of these, and it’s all gone. I presume that this is some sort of sector-rotation move by the foundation’s investment advisors
Posted in: Clinical Trials | 0 Comments »
Read the full story
Business Week – Drug Marketing
Business Week – Pharma Marketing
Cafe Pharma
Clinical Trials.gov
FDA on Twitter
Pharma Live
Pharma Voice